Current treatment options for epilepsy are inadequate, as too many patients suffer from uncontrolled seizures and from negative side effects of treatment. In addition to these clinical challenges, our scientific understanding of epilepsy is incomplete. Optogenetic and designer receptor technologies provide unprecedented and much needed specificity, allowing for spatial, temporal and cell type-selective modulation of neuronal circuits. Using such tools, it is now possible to begin to address some of the fundamental unanswered questions in epilepsy, to dissect epileptic neuronal circuits and to develop new intervention strategies. Such specificity of intervention also has the potential for direct therapeutic benefits, allowing healthy tissue and network functions to continue unaffected. In this Perspective, we discuss promising uses of these technologies for the study of seizures and epilepsy, as well as potential use of these strategies for clinical therapies.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
England, M.J., Liverman, C.T., Schultz, A.M. & Strawbridge, L.M. Epilepsy across the spectrum: promoting health and understanding. A summary of the Institute of Medicine report. Epilepsy Behav. 25, 266–276 (2012).
Perucca, P. & Gilliam, F.G. Adverse effects of antiepileptic drugs. Lancet Neurol. 11, 792–802 (2012).
Laxer, K.D. et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 37C, 59–70 (2014).
Duchowny, M. & Bhatia, S. Epilepsy: preserving memory in temporal lobectomy-are networks the key? Nat. Rev. Neurol. 10, 245–246 (2014).
de Tisi, J. et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet 378, 1388–1395 (2011).
Engel, J. Jr. et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Epilepsia 44, 741–751 (2003).
Krook-Magnuson, E., Ledri, M., Soltesz, I. & Kokaia, M. How might novel technologies such as optogenetics lead to better treatments in epilepsy? Adv. Exp. Med. Biol. 813, 319–336 (2014).
Wang, J., Faust, S.M. & Rabinowitz, J.E. The next step in gene delivery: molecular engineering of adeno-associated virus serotypes. J. Mol. Cell. Cardiol. 50, 793–802 (2011).
Burger, C. et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Therapy 10, 302–317 (2004).
Visel, A. et al. A high-resolution enhancer atlas of the developing telencephalon. Cell 152, 895–908 (2013).
Zhang, F. et al. Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. Nat. Protoc. 5, 439–456 (2010).
Schnutgen, F. et al. A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. Nat. Biotechnol. 21, 562–565 (2003).
Atasoy, D., Aponte, Y., Su, H.H. & Sternson, S.M. A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping. J. Neurosci. 28, 7025–7030 (2008).
Gradinaru, V. et al. Molecular and cellular approaches for diversifying and extending optogenetics. Cell 141, 154–165 (2010).
Fenno, L.E. et al. Targeting cells with single vectors using multiple-feature Boolean logic. Nat. Methods 11, 763–772 (2014).
Paz, J.T. et al. Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat. Neurosci. 16, 64–70 (2013).
Armstrong, C., Krook-Magnuson, E., Oijala, M. & Soltesz, I. Closed-loop optogenetic intervention in mice. Nat. Protoc. 8, 1475–1493 (2013).
Krook-Magnuson, E., Armstrong, C., Oijala, M. & Soltesz, I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat. Commun. 4, 1376 (2013).
Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S. & Roth, B.L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. USA 104, 5163–5168 (2007).
Guettier, J.M. et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc. Natl. Acad. Sci. USA 106, 19197–19202 (2009).
Nakajima, K. & Wess, J. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol. Pharmacol. 82, 575–582 (2012).
Katzel, D., Nicholson, E., Schorge, S., Walker, M.C. & Kullmann, D.M. Chemical-genetic attenuation of focal neocortical seizures. Nat. Commun. 5, 3847 (2014).
Sukhotinsky, I. et al. Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model. PLoS ONE 8, e62013 (2013).
Berglind, F. et al. Optogenetic inhibition of chemically induced hypersynchronized bursting in mice. Neurobiol. Dis. 65, 133–141 (2014).
Chiang, C.C., Ladas, T.P., Gonzalez-Reyes, L.E. & Durand, D.M. Seizure suppression by high frequency optogenetic stimulation using in vitro and in vivo animal models of epilepsy. Brain Stimulat. 7, 890−899 (2014).
Wykes, R.C. et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci. Transl. Med. 4, 161ra152 (2012).
Krook-Magnuson, E., Szabo, G.G., Armstrong, C., Oijala, M. & Soltesz, I. Cerebellar directed optogenetic intervention inhibits spontaneous hippocampal seizures in a mouse model of temporal lobe epilepsy. eNeruo 1 published online, doi:10.1523/eneuro.0005-14.2014 (December 2014).
Tonnesen, J., Sorensen, A.T., Deisseroth, K., Lundberg, C. & Kokaia, M. Optogenetic control of epileptiform activity. Proc. Natl. Acad. Sci. USA 106, 12162–12167 (2009).
Selvaraj, P., Sleigh, J.W., Freeman, W.J., Kirsch, H.E. & Szeri, A.J. Open loop optogenetic control of simulated cortical epileptiform activity. J. Comput. Neurosci. 36, 515–525 (2014).
Alexander, G.M. et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63, 27–39 (2009).
Krook-Magnuson, E., Varga, C., Lee, S.H. & Soltesz, I. New dimensions of interneuronal specialization unmasked by principal cell heterogeneity. Trends Neurosci. 35, 175–184 (2012).
Lee, S.H. et al. Parvalbumin-positive basket cells differentiate among hippocampal pyramidal cells. Neuron 82, 1129–1144 (2014).
Brown, S.P. & Hestrin, S. Cell-type identity: a key to unlocking the function of neocortical circuits. Curr. Opin. Neurobiol. 19, 415–421 (2009).
Bragin, A., Engel, J. Jr., Wilson, C.L., Vizentin, E. & Mathern, G.W. Electrophysiologic analysis of a chronic seizure model after unilateral hippocampal KA injection. Epilepsia 40, 1210–1221 (1999).
Haussler, U., Bielefeld, L., Froriep, U.P., Wolfart, J. & Haas, C.A. Septotemporal position in the hippocampal formation determines epileptic and neurogenic activity in temporal lobe epilepsy. Cereb. Cortex 22, 26–36 (2012).
Bezaire, M.J. & Soltesz, I. Quantitative assessment of CA1 local circuits: Knowledge base for interneuron-pyramidal cell connectivity. Hippocampus 23, 751−785 (2013).
Jiruska, P. et al. Synchronization and desynchronization in epilepsy: controversies and hypotheses. J. Physiol. (Lond.) 591, 787–797 (2013).
Coulter, D.A. Algal proteins illuminate epilepsy. Epilepsy Currents 13, 221–223 (2013).
Osawa, S. et al. Optogenetically induced seizure and the longitudinal hippocampal network dynamics. PLoS ONE 8, e60928 (2013).
Madisen, L. et al. A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing. Nat. Neurosci. 15, 793–802 (2012).
Chuong, A.S. et al. Noninvasive optical inhibition with a red-shifted microbial rhodopsin. Nat. Neurosci. 17, 1123−1129 (2014).
Yizhar, O. et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477, 171–178 (2011).
Lin, J.Y., Knutsen, P.M., Muller, A., Kleinfeld, D. & Tsien, R.Y. ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. Nat. Neurosci. 16, 1499–1508 (2013).
Zhang, F. et al. Red-shifted optogenetic excitation: a tool for fast neural control derived from Volvox carteri. Nat. Neurosci. 11, 631–633 (2008).
Berndt, A., Lee, S.Y., Ramakrishnan, C. & Deisseroth, K. Structure-guided transformation of channelrhodopsin into a light-activated chloride channel. Science 344, 420–424 (2014).
Simonato, M. et al. Progress in gene therapy for neurological disorders. Nat. Rev. Neurology 9, 277–291 (2013).
Bartus, R.T., Weinberg, M.S. & Samulski, R.J. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol. Therapy 22, 487–497 (2014).
Bartus, R.T. et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80, 1698–1701 (2013).
Murphy, A.M. & Rabkin, S.D. Current status of gene therapy for brain tumors. Transl. Res. 161, 339–354 (2013).
Worgall, S. et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19, 463–474 (2008).
Kullmann, D.M., Schorge, S., Walker, M.C. & Wykes, R.C. Gene therapy in epilepsy-is it time for clinical trials? Nat. Rev. Neurology 10, 300–304 (2014).
Duque, S. et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Therapy 17, 1187–1196 (2009).
Gray, S.J. et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Therapy 18, 570–578 (2010).
Drexel, M., Kirchmair, E., Wieselthaler-Holzl, A., Preidt, A.P. & Sperk, G. Somatostatin and neuropeptide Y neurons undergo different plasticity in parahippocampal regions in kainic acid-induced epilepsy. J. Neuropathol. Exp. Neurol. 71, 312–329 (2012).
Han, X. et al. A high-light sensitivity optical neural silencer: development and application to optogenetic control of non-human primate cortex. Front. Syst. Neurosci. 5, 18 (2011).
Pei, Y., Rogan, S.C., Yan, F. & Roth, B.L. Engineered GPCRs as tools to modulate signal transduction. Physiology 23, 313–321 (2008).
Kim, T.I. et al. Injectable, cellular-scale optoelectronics with applications for wireless optogenetics. Science 340, 211–216 (2013).
Stark, E., Koos, T. & Buzsaki, G. Diode probes for spatiotemporal optical control of multiple neurons in freely moving animals. J. Neurophysiol. 108, 349–363 (2012).
Cook, M.J. et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol. 12, 563–571 (2013).
Heck, C.N. et al. Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial. Epilepsia 55, 432–441 (2014).
Wess, J., Nakajima, K. & Jain, S. Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol. Sci. 34, 385–392 (2013).
Jann, M.W., Lam, Y.W. & Chang, W.H. Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Arch. Int. Pharmacodyn. Ther. 328, 243–250 (1994).
EGFP Collaborative. et al. The epilepsy phenome/genome project. Clin. Trials 10, 568–586 (2013).
Liu, Y. et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann. Neurol. 74, 128–139 (2013).
Henderson, K.W. et al. Long-term seizure suppression and optogenetic analyses of synaptic connectivity in epileptic mice with hippocampal grafts of GABAergic interneurons. J. Neurosci. 34, 13492–13504 (2014).
Vezzani, A. The promise of gene therapy for the treatment of epilepsy. Expert Rev. Neurother. 7, 1685–1692 (2007).
Sorensen, A.T. et al. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp. Neurol. 215, 328–333 (2009).
Caroni, P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J. Neurosci. Methods 71, 3–9 (1997).
Airan, R.D., Thompson, K.R., Fenno, L.E., Bernstein, H. & Deisseroth, K. Temporally precise in vivo control of intracellular signalling. Nature 458, 1025–1029 (2009).
Zhang, F. et al. Multimodal fast optical interrogation of neural circuitry. Nature 446, 633–639 (2007).
Chow, B.Y. et al. High-performance genetically targetable optical neural silencing by light-driven proton pumps. Nature 463, 98–102 (2010).
Gradinaru, V. et al. Targeting and readout strategies for fast optical neural control in vitro and in vivo. J. Neurosci. 27, 14231–14238 (2007).
Toettcher, J.E., Weiner, O.D. & Lim, W.A. Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module. Cell 155, 1422–1434 (2013).
Konermann, S. et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature 500, 472–476 (2013).
Motta-Mena, L.B. et al. An optogenetic gene expression system with rapid activation and deactivation kinetics. Nat. Chem. Biol. 10, 196–202 (2014).
This work was funded by US National Institutes of Health grants NS35915 and NS74702 (to I.S.), a Citizens United for Research in Epilepsy (CURE) Taking Flight Award (to E.K.-M.), and a US National Institutes of Health grant K99NS087110 (to E.K.-M.).
The authors declare no competing financial interests.
About this article
Cite this article
Krook-Magnuson, E., Soltesz, I. Beyond the hammer and the scalpel: selective circuit control for the epilepsies. Nat Neurosci 18, 331–338 (2015). https://doi.org/10.1038/nn.3943
Causal relationship of CA3 back-projection to the dentate gyrus and its role in CA1 fast ripple generation
BMC Neuroscience (2021)
Analog Integrated Circuits and Signal Processing (2019)
Low frequency transcranial electrical stimulation does not entrain sleep rhythms measured by human intracranial recordings
Nature Communications (2017)
Molecular Neurobiology (2017)
Nature Reviews Drug Discovery (2016)